# Chronic Kidney Disease Market

> Chronic Kidney Disease Market Research Report Information by Diagnosis (Blood Test, Urine Test, Imaging Test, and Kidney Biopsy), by Treatment (Drugs, Dialysis, and Kidney Transplant) , by Indication (Type 1 Or Type 2 Diabetes, High Blood Pressure, and Polycystic Kidney Disease), by End User (Hospital & Clinics and Diagnostic Centers), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.78%
- **2024:** $ 40.53 Billion
- **2025:** $ 42.87 Billion
- **2035:** $ 75.22 Billion
- **Key Players:** Companies such as Fresenius Medical Care (DE), DaVita Inc. (US), Baxter International Inc. (US), Abbott Laboratories (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (CH), Sanofi S.A. (FR), Merck & Co., Inc. (US) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/4289-HCR · **Pages:** 110 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** July 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744

---

## Market Summary

The Global Chronic Kidney Disease Market size was valued at USD 40.53 Billion in 2024, and the market is projected to grow from USD 42.87 Billion in 2025 to USD 75.22 Billion by 2035, registering a CAGR of 5.78% during the forecast period 2025–2035. North America led the market in 2024 with over 45% share, generating around USD 18.24 Billion in revenue.
 
The Chronic Kidney Disease Market is primarily driven by the rapidly increasing global burden of diabetes, hypertension, and aging populations, which significantly raise the risk of kidney dysfunction. Growing awareness regarding early diagnosis and expanding access to advanced treatment options are further accelerating market expansion worldwide.
 
According to the Centers for Disease Control and Prevention, nearly 35.5 million U.S. adults are estimated to have chronic kidney disease, while diabetes and hypertension remain the leading contributors. Additionally, the World Health Organization highlights the growing global elderly population, expected to reach 1.4 billion people aged 60 years and above by 2030, increasing CKD treatment demand significantly.

## Market Drivers

### Government Initiatives and Funding

Government initiatives and funding aimed at combating chronic kidney disease are pivotal in shaping the global market. Various health organizations are allocating resources to enhance research, improve treatment accessibility, and promote awareness campaigns. For instance, funding for kidney disease research has seen a notable increase, which is expected to lead to the development of novel therapies and technologies. 
 
Additionally, public health policies that focus on CKD prevention and management are likely to create a more favorable environment for market growth. These initiatives not only support patients but also encourage innovation within the industry, fostering a landscape conducive to advancements in CKD treatment.

### Increased Focus on Preventive Healthcare

The shift towards preventive healthcare is reshaping the global market. Healthcare providers are increasingly emphasizing early detection and management of CKD to mitigate its progression. This trend is supported by initiatives aimed at educating the public about risk factors and the importance of regular health screenings. 
 
As a result, there is a growing demand for diagnostic tools and monitoring devices that facilitate early intervention. The global industry for such technologies is expected to expand, driven by the need for effective preventive measures. Furthermore, the integration of preventive strategies into healthcare systems is likely to enhance patient outcomes and reduce the overall burden of CKD, thereby influencing market dynamics.

### Advancements in Renal Replacement Therapies

Innovations in renal replacement therapies, including dialysis and kidney transplantation, are significantly influencing the Chronic Kidney Disease Market Industry. The development of more efficient dialysis machines and improved transplantation techniques has enhanced patient outcomes and quality of life. For instance, the introduction of home dialysis options has expanded access to treatment, allowing patients to manage their condition more effectively. 
 
The global market for renal replacement therapies is projected to grow substantially, with estimates suggesting a compound annual growth rate (CAGR) of over 5% in the coming years. This growth is indicative of the increasing investment in research and development aimed at improving renal therapies, which is crucial for addressing the needs of CKD patients.

### Rising Prevalence of Chronic Kidney Disease

The increasing incidence of chronic kidney disease (CKD) is a primary driver of the Chronic Kidney Disease Market Industry. According to recent estimates, approximately 10% of the population is affected by CKD, with numbers expected to rise due to factors such as aging populations and the prevalence of diabetes and hypertension. 
 
This growing patient base necessitates enhanced treatment options and diagnostic tools, thereby propelling market growth. The global market is witnessing a surge in demand for innovative therapies and management solutions, as healthcare systems strive to address the needs of this expanding demographic. As awareness of CKD increases, more individuals are seeking medical attention, further driving the market's expansion.

### Growing Demand for Home-Based Care Solutions

The rising demand for home-based care solutions is transforming the Chronic Kidney Disease Market Industry. Patients increasingly prefer receiving care in the comfort of their homes, which has led to a surge in the development of home dialysis systems and telehealth services. This trend is driven by the desire for greater convenience, improved quality of life, and reduced healthcare costs. 
 
Market analysts project that the home healthcare segment will experience significant growth, with an expected CAGR of around 7% over the next few years. This shift not only reflects changing patient preferences but also highlights the need for innovative solutions that cater to the unique challenges faced by CKD patients, thereby influencing the overall market landscape.

## Future Outlook

The Chronic Kidney Disease Market size is projected to reach USD 42.87 Billion by 2035, growing at a CAGR of 5.78%, driven by increasing prevalence, advancements in treatment technologies, and rising healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection Expansion of home dialysis solutions to enhance patient convenience

By 2035, Chronic Kidney Disease Market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Diagnosis: Blood Test (Largest) vs. Kidney Biopsy (Fastest-Growing)

In the Chronic Kidney Disease Market, the diagnosis segment is primarily led by blood tests, which capture the largest market share of 42% due to their widespread use for initial screening and monitoring of kidney function. Urine tests and imaging tests also play crucial roles but hold smaller market shares. The performance of kidney biopsy, while historically niche, is experiencing a significant upward trend, further diversifying the diagnostic landscape of CKD.

Blood Tests: Dominant vs. Kidney Biopsies: Emerging

Blood tests are a dominant force in the diagnostic segment for market. They are favored for their efficiency and ability to provide crucial information about renal function through markers like serum creatinine and estimated glomerular filtration rate (eGFR). On the other hand, kidney biopsies, while once considered invasive, are emerging rapidly due to advancements in [precision](https://www.marketresearchfuture.com/reports/precision-oncology-market-21854)medicine. They offer invaluable insights into the underlying causes of CKD, thus playing a critical role in personalized treatment approaches. As awareness and research in nephrology grow, the adoption of kidney biopsies is projected to increase significantly, positioning them as a vital tool in CKD diagnosis.

### By Treatment: Dialysis (Largest) vs. Kidney Transplant (Fastest-Growing)

In the Chronic Kidney Disease Market, the treatment segment is highly diversified, consisting mainly of Drugs, Dialysis, and Kidney Transplant. Within this segment, Dialysis holds the largest market share of 48% due to the increasing prevalence of end-stage renal disease and the steady demand for dialysis therapies. In contrast, while Drug therapies also play a significant role, they do not dominate the global market as much as Dialysis. Kidney Transplant, although currently smaller in market share, is witnessing rapid adoption as advancements in surgical techniques and technology improve outcomes for patients, leading to wider acceptance.

Dialysis (Dominant) vs. Kidney Transplant (Emerging)

Dialysis remains the dominant treatment option in the global industry, characterized by its established infrastructure and a large patient base reliant on regular sessions for renal function support. This modality is crucial for managing patients until they reach kidney transplant eligibility. On the other hand, Kidney Transplant is emerging rapidly due to increased awareness of organ donation and significant advancements in immunosuppressive therapies. Enhanced performance and positive patient outcomes are driving growth, making transplantation a preferred choice among clinicians and patients alike. As healthcare facilities expand transplant programs and collaborate more with donor organizations, the transplant segment is expected to increase its share in the overall market significantly.

### By Indication: High Blood Pressure (Largest) vs. Type 1 Or Type 2 Diabetes (Fastest-Growing)

In the Chronic Kidney Disease Market, high blood pressure emerges as the largest indication, significantly contributing to the prevalence of CKD. This segment holds a substantial share of 39%, driven by the increasing incidence of hypertension among adults and the complications it brings to kidney health. In contrast, the diabetes-related segment, comprising Type 1 and Type 2 diabetes, is gaining traction as the fastest-growing indication, driven by the global surge in diabetes cases influenced by lifestyle changes and obesity. The growth trends within the indication segment indicate a shifting focus towards managing diabetes as a critical factor in CKD progression. As healthcare strategies evolve, awareness and early diagnosis of diabetes-related kidney complications are becoming paramount. This trend is further propelled by advancements in diabetes management and prevention programs aimed at reducing the risk of CKD among diabetic patients, which fosters a growing market for related therapies and solutions.

High Blood Pressure (Dominant) vs. Type 1 Or Type 2 Diabetes (Emerging)

High blood pressure, a predominant factor in the Chronic Kidney Disease Market, substantially impacts the kidney’s ability to function, leading to increased demand for therapies aimed at managing hypertension. The segment benefits from established treatment protocols and a broad patient base, reinforcing its dominant position. Conversely, Type 1 and Type 2 diabetes represent an emerging segment, driven by rising prevalence due to sedentary lifestyles and dietary changes. This segment is characterized by the urgent need for effective diabetes management solutions to prevent kidney damage, presenting significant opportunities for innovation and market expansion. With greater emphasis on integrated care, the diabetes-related segment is rapidly evolving to address the complexities of CKD, thereby enhancing its overall market relevance.

### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the Chronic Kidney Disease Market (CKD) market, the distribution of market share of 52% among end users reflects the significance of healthcare institutions in managing treatment. Hospitals and clinics hold a substantial portion of this market due to their capacity to provide comprehensive care, including dialysis and transplantation services. Diagnostic centers, while smaller in comparison, play a crucial role in early detection and ongoing monitoring of CKD, contributing to their increasing share as the focus on preventive healthcare intensifies.

End User: Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals and clinics remain the dominant end users in the market, leveraging their extensive resources, staff expertise, and integrated services to manage CKD patients effectively. They are equipped with advanced medical equipment to conduct diagnoses and treatments, making them the primary choice for patients requiring immediate and ongoing medical attention. In contrast, diagnostic centers are emerging as essential players, reflecting a shift towards specialized, outpatient care. These centers focus on advanced diagnostic testing, which aids in the early identification and management of CKD, appealing particularly to patients seeking convenience and prompt results. Their growth is driven by an increase in awareness about kidney health and the importance of early intervention.

## Regional Market Share Analysis

### North America : Healthcare Innovation Leader

North America is the largest market for Chronic Kidney Disease Market (CKD) treatment, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of diabetes and hypertension, and significant investments in research and development. Regulatory support from agencies like the FDA further drives innovation and accessibility of new therapies.

The United States is the leading country in this market, with major players such as Fresenius Medical Care and DaVita Inc. dominating the landscape. The competitive environment is characterized by a focus on innovative treatment options, including dialysis and kidney transplantation. The presence of key players ensures a robust supply chain and continuous advancements in patient care.

- According to the Centers for Disease Control and Prevention, more than 1 in 7 U.S. adults are estimated to have chronic kidney disease, representing nearly 35.5 million people. Additionally, diabetes affects over 38 million Americans, significantly increasing CKD treatment demand and supporting continued market expansion across the region.

### Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for market, accounting for approximately 30% of the global market share. The region is witnessing growth driven by increasing awareness of CKD, supportive healthcare policies, and a rising aging population. Regulatory frameworks are evolving to enhance patient access to innovative treatments, which is expected to further stimulate market growth.

Leading countries in Europe include Germany, France, and the UK, where healthcare systems are increasingly prioritizing CKD management. Key players like Novartis AG and Sanofi S.A. are actively involved in developing new therapies. The competitive landscape is marked by collaborations between pharmaceutical companies and healthcare providers to improve patient outcomes and streamline treatment protocols.

- The World Health Organization reports that noncommunicable diseases account for nearly 90% of all deaths in the European region, with diabetes and cardiovascular disorders significantly contributing to kidney disease prevalence. Increasing chronic disease management initiatives and healthcare modernization efforts continue strengthening CKD treatment adoption throughout Europe.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is an emerging powerhouse in the market, holding about 20% of the global market share. The region's growth is fueled by increasing urbanization, rising disposable incomes, and a growing prevalence of lifestyle-related diseases. Governments are also implementing policies to enhance healthcare access and improve CKD management, which is expected to drive market expansion further.

Countries like China and India are at the forefront of this growth, with significant investments in healthcare infrastructure. The competitive landscape features both local and international players, including Baxter International Inc. and Abbott Laboratories. The presence of these key players is crucial for addressing the rising demand for effective CKD treatments and improving patient care across the region.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents a smaller segment of the market, accounting for approximately 5% of the global share. However, it presents significant growth opportunities due to increasing awareness of CKD and the rising burden of non-communicable diseases. Governments are beginning to recognize the importance of CKD management, leading to gradual improvements in healthcare policies and infrastructure.

Countries like South Africa and the UAE are emerging as key players in CKD treatment, with a growing number of healthcare facilities and initiatives aimed at improving patient outcomes. The competitive landscape is still developing, with both local and international companies looking to establish a foothold in this untapped market, focusing on innovative treatment solutions and patient education.

## Competitive Benchmarking

The Chronic Kidney Disease Market (CKD) Market is characterized by a complex interplay of competitive dynamics, driven by an increasing prevalence of kidney diseases and a growing demand for innovative treatment options. Key players such as Fresenius Medical Care (DE), DaVita Inc. (US), and Baxter International Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Fresenius Medical Care (DE) focuses on expanding its dialysis services globally, while DaVita Inc. (US) emphasizes patient-centric care models and integrated healthcare solutions.
 
Baxter International Inc. (US) is investing in advanced renal therapies, indicating a trend towards innovation and technological advancement that collectively shapes the competitive landscape. The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. This strategy not only reduces costs but also improves responsiveness to regional market demands.
 
The collective influence of these key players fosters a competitive environment where innovation and operational excellence are paramount. In August 2025, DaVita Inc. (US) announced a strategic partnership with a leading telehealth provider to enhance [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) capabilities. This move is significant as it aligns with the growing trend of digital health solutions, enabling more effective management of CKD patients and potentially improving health outcomes. By integrating telehealth services, DaVita Inc. (US) positions itself as a leader in patient engagement and care delivery.
 
In September 2025, Baxter International Inc. (US) launched a new home dialysis system designed to improve patient convenience and treatment adherence. This innovation is crucial as it reflects the increasing shift towards home-based therapies, which are becoming more favorable among patients. By prioritizing patient-centric solutions, Baxter International Inc. (US) enhances its competitive edge in the market. In July 2025, Fresenius Medical Care (DE) expanded its operations in Asia by acquiring a regional dialysis provider.
 
This acquisition not only strengthens its market presence in a rapidly growing region but also underscores the importance of strategic mergers and acquisitions in achieving growth objectives. Such actions are indicative of a broader trend where companies seek to consolidate their positions in emerging markets. As of October 2025, the CKD market is witnessing transformative trends such as digitalization, sustainability, and the integration of artificial intelligence in treatment protocols.
 
Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage complementary strengths. Moving forward, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability, reflecting a shift towards more sustainable and patient-centered care.

## Recent News & Developments

- **Q2 2024: Novo Nordisk receives FDA approval for Ozempic® (semaglutide) to reduce risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease** Novo Nordisk announced FDA approval for an expanded indication of Ozempic® (semaglutide), which now includes reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, a population at high risk for chronic kidney disease.
- **Q2 2024: AstraZeneca’s Farxiga approved in China for the treatment of chronic kidney disease** AstraZeneca received regulatory approval in China for Farxiga (dapagliflozin) for the treatment of chronic kidney disease, expanding its market presence in Asia for CKD therapies.
- **Q1 2024: Renalytix Announces FDA Clearance of KidneyIntelX.dkd Test for Early-Stage Diabetic Kidney Disease** Renalytix received FDA clearance for its KidneyIntelX.dkd test, designed to assess risk and guide management in patients with early-stage diabetic kidney disease.
- **Q2 2024: Novo Nordisk to acquire Cardior Pharmaceuticals for up to 1 billion euros** Novo Nordisk announced the acquisition of Cardior Pharmaceuticals, a German biotech focused on RNA-based therapies for heart and kidney diseases, for up to 1 billion euros.
- **Q2 2024: Goldfinch Bio secures $100M Series C to advance kidney disease pipeline** Goldfinch Bio raised $100 million in Series C funding to support the development of its pipeline targeting chronic kidney disease.
- **Q1 2024: Otsuka and Astex Pharmaceuticals Announce FDA Approval of XRO-001 for Autosomal Dominant Polycystic Kidney Disease** Otsuka and Astex Pharmaceuticals received FDA approval for XRO-001, a new therapy for autosomal dominant polycystic kidney disease, a major cause of chronic kidney disease.
- **Q2 2024: Tricida Announces Completion of Enrollment in VALOR-CKD Phase 3 Trial** Tricida completed patient enrollment for its VALOR-CKD Phase 3 trial, evaluating veverimer for the treatment of metabolic acidosis in chronic kidney disease.
- **Q1 2024: Outset Medical Announces FDA Clearance of TabloCart for Home Dialysis** Outset Medical received FDA clearance for TabloCart, a new accessory for its Tablo Hemodialysis System, enabling more flexible home dialysis for chronic kidney disease patients.
- **Q2 2024: Bayer launches Kerendia in Japan for chronic kidney disease associated with type 2 diabetes** Bayer announced the launch of Kerendia (finerenone) in Japan, expanding access to its treatment for chronic kidney disease associated with type 2 diabetes.
- **Q1 2024: Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (omaveloxolone) for Friedreich’s Ataxia** Reata Pharmaceuticals received FDA approval for SKYCLARYS™ (omaveloxolone), which is being investigated for potential benefits in chronic kidney disease due to its mechanism of action.
- **Q2 2024: Akebia Therapeutics Announces European Commission Approval of Vafseo® (vadadustat) for Anemia Associated with market** Akebia Therapeutics received European Commission approval for Vafseo® (vadadustat), a treatment for anemia in patients with chronic kidney disease.
- **Q1 2024: Renalytix Announces Partnership with DaVita to Expand KidneyIntelX Testing in U.S. [Dialysis Centers](https://www.marketresearchfuture.com/reports/dialysis-centers-market-66486)** Renalytix entered a partnership with DaVita to expand the use of KidneyIntelX testing in U.S. dialysis centers, aiming to improve risk assessment and management for chronic kidney disease patients.

## Report Scope

| MARKET SIZE 2024 | 40.53(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 42.87(USD Billion) |
| MARKET SIZE 2035 | 75.22(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.78% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Fresenius Medical Care (DE), DaVita Inc. (US), Baxter International Inc. (US), Abbott Laboratories (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (CH), Sanofi S.A. (FR), Merck & Co., Inc. (US) |
| Segments Covered | Diagnosis, Treatment, Indication, End User, Region |
| Key Market Opportunities | Advancements in personalized medicine enhance treatment options in the Chronic Kidney Disease Market. |
| Key Market Dynamics | Rising prevalence of chronic kidney disease drives demand for innovative treatment options and enhanced patient management solutions. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the market in 2035?**
A: The projected market valuation for the market in 2035 is 75.22 USD Billion.

**Q: What was the market valuation for the market in 2024?**
A: The overall market valuation for the market was 40.53 USD Billion in 2024.

**Q: What is the expected CAGR for the Chronic Kidney Disease Market from 2025 to 2035?**
A: The expected CAGR for the Chronic Kidney Disease Market during the forecast period 2025 - 2035 is 5.78%.

**Q: Which companies are considered key players in the market?**
A: Key players in the market include Fresenius Medical Care, DaVita Inc., Baxter International Inc., and Abbott Laboratories.

**Q: What are the main segments of the Chronic Kidney Disease Market?**
A: The main segments of the Chronic Kidney Disease Market include Diagnosis, Treatment, Indication, and End User.

**Q: What was the valuation of the Diagnosis segment in 2024?**
A: In 2024, the Diagnosis segment was valued at approximately 40.53 USD Billion.

**Q: How much is the Treatment segment projected to be worth by 2035?**
A: The Treatment segment is projected to be worth between 30.0 and 35.0 USD Billion by 2035.

**Q: What are the projected values for the End User segment in 2035?**
A: The End User segment is projected to reach between 46.0 and 50.0 USD Billion by 2035.

**Q: What indications are driving the Chronic Kidney Disease Market?**
A: Indications driving the market include Type 1 or Type 2 Diabetes, High Blood Pressure, and Polycystic Kidney Disease.

**Q: What is the projected growth for the Imaging Test segment by 2035?**
A: The Imaging Test segment is projected to grow to between 22.0 and 25.0 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744*